AAAizhan Akhayeva

Aizhan Akhayeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aizhan Akhayeva has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lyophilized Mesenchymal Stromal Cell-Derived Products in Regenerative Medicine: A Systematic Review of Biological Activity, Stability, Safety, and Therapeutic Effects

    by Bolat Sadykov, Abay Baigenzhin, Anastassiya Ganina, Madina Karimova, Aizhan Akhayeva, Anuar Zhunussov, Batyrbek Assembekov, Ildar Fakhradiyev

    Background/Objectives: Lyophilization may facilitate storage and distribution of mesenchymal stromal cell (MSC)-derived products. This systematic review assessed biological activity, storage stability, safety, and therapeutic effects of lyophilized MSC-derived products in regenerative medicine. Methods: PubMed, Scopus, and Web of Science Core Collection were searched through 28 August 2026. Eligible English-language original studies included in vivo animal or human therapeutic evaluations. The review was registered in PROSPERO (CRD420261426429) and reported following PRISMA 2020. Two reviewers independently selected studies, extracted data, and assessed risk of bias using SYRCLE, RoB 2, or ROBINS-I according to study design. Heterogeneity precluded meta-analysis; findings were synthesized narratively. Results: Thirty-nine studies were included from 884 records; only one contained a human interventional component. Products included conditioned medium, secretome, extracellular vesicles, and whole-cell or synthetic preparations. Sixteen studies evaluated biological activity or stability: 12 directly compared lyophilized and fresh or non-lyophilized products, whereas four assessed post-lyophilization activity without a fresh or non-lyophilized comparator. Retention depended on product formulation and processing conditions, and storage-stability evidence was limited. Twelve studies provided safety evidence; no major systemic toxicity signal emerged, although concentration-dependent cytotoxicity in vitro and transient local reactions occurred. Most studies reported improvement in at least one regenerative or functional outcome, with neutral or mixed findings in some applications. Incomplete reporting of randomization and blinding limited confidence in the evidence. Conclusions: Some lyophilized MSC-derived products retain biological properties and exhibit therapeutic activity, predominantly in preclinical models. Evidence is insufficient to establish clinical efficacy or long-term safety. Translation requires standardized manufacturing, validated potency and storage-stability testing, systematic safety assessment, and well-designed human studies.

  • Open Access

    Hepatic and Renal Responses to Mesenchymal Stromal Cell Therapy: Mechanisms and Biochemical Evidence

    by Nursulu Z. Altaeva, Baglan B. Kazhiyakhmetova, Balkiya M. Abdrakhmanova, Beksultan K. Mussin, Ardak O. Sapieva, Dinara S. Tarzhanova, Tanzira T. Yedilbayeva, Anastassiya M. Ganina, Tatyana S. Bulavinceva, Sapargul Marat, et al.

    Mesenchymal stromal cell (MSC) therapy is being investigated for hepatic and renal disorders, but biochemical changes do not necessarily establish organ regeneration or clinical benefit. This non-exhaustive narrative review evaluates direct MSC interventions and six blood analytes: alanine aminotransferase, aspartate aminotransferase, total bilirubin, total protein, urea, and creatinine. PubMed-indexed English-language studies published from 2000 through 11 October 2026 were considered when complete texts and relevant findings were accessible; reviews and methodological sources provide background. Evidence is interpreted by species, disease, specimen, cell product, comparison type, and follow-up. Proposed mechanisms include paracrine signaling, immunomodulation, and host responses to administered cells, with varying experimental support. Selected preclinical studies report biochemical improvements, whereas human findings are heterogeneous. Serum total-protein responses are limited and product-dependent, and direct serum-urea evidence is mainly preclinical. The ACT-AKI trial found no acceleration of creatinine-defined recovery, while a randomized cirrhosis follow-up showed a within-arm bilirubin decline without a significant between-group difference. Urea nitrogen, albumin, urinary protein, and filtration outcomes are distinguished from the specified concentrations. Findings are synthesized descriptively, with explicit source uncertainties. Standardized cell characterization and controlled trials combining biochemical, histological, and functional outcomes are needed to assess durable clinical benefit.

  • Open Access

    Manufacturing of Placenta- and Umbilical Cord-Derived Mesenchymal Stromal Cells: A Systematic Scoping Review of Process Parameters, Quality Attributes, and Evidence-to-Control Relationships

    by Bolat Sadykov, Abay Baigenzhin, Anastassiya Ganina, Madina Karimova, Aizhan Akhayeva, Anuar Zhunussov, Batyrbek Assembekov, Ildar Fakhradiyev

    The manufacturing of placenta- and umbilical cord-derived mesenchymal stromal cells (MSCs) varies across anatomical starting material, isolation, culture supplementation, expansion, scale-up, cryopreservation, and release testing. This variability limits comparability between products and complicates process transfer. The study aimed to map full-text evidence on manufacturing variables, process outcomes, candidate critical material attributes (CMAs), candidate critical process parameters (CPPs), critical quality attributes (CQAs), potency assays, and release strategies for human placenta- and umbilical cord-derived MSCs. A systematic scoping review was conducted using a Population–Concept–Context framework and reported according to PRISMA-ScR, with search reporting guided by PRISMA-S. Searches without publication-date restrictions were completed on 15 August 2026. Two reviewers independently screened records and full texts, and charted data were independently verified. Findings were mapped by manufacturing contrast and outcome domain; quantitative pooling was considered only when biological, process, and methodological comparability supported an interpretable common effect estimate. The primary Scopus/Web of Science search identified 18,860 records; 13,122 unique records were screened and 439 full-text reports were assessed. After 208 exclusions, 231 manufacturing reports remained; the PubMed/MEDLINE search and backward/forward citation searching contributed two and five additional unique eligible reports, respectively, after cross-source deduplication, yielding 238 included reports. The study-family sensitivity set contained 236 distinct study families after linked-report assessment. Tissue-source coding identified 183 umbilical cord/Wharton’s jelly reports, 46 placental reports, and nine multi-source perinatal reports. The most frequent domains were expansion/passaging/senescence (94/238; 39.5%), media/supplements (69; 29.0%), isolation/tissue processing (67; 28.2%), and GMP/quality/release (48; 20.2%). Direct-comparison sets included 2D versus 3D/bioreactor expansion (23 reports), explant versus enzymatic isolation (22), fresh/native versus cryopreserved material (19), HPL versus FBS (12), and hypoxia versus normoxia (10). Differences in intervention definition, tissue compartment, passage/timepoint, endpoint, and unit did not support a coherent common pooled effect. The mapped evidence supports an end-to-end development model and does not identify a universal manufacturing recipe. Anatomical starting material, isolation, culture conditions, cumulative population doublings, scale-up, cryopreservation, and potency-linked release should be treated as interdependent elements of product comparability. Formal designation of CMAs and CPPs remains product- and platform-specific and requires evidence that links process variation to relevant CQAs.

  • Open Access

    Intradermal Application of Allogenic Wharton’s Jelly Mesenchymal Stem Cells for Chronic Post-Thoracotomy Wound in an Elderly Patient After Coronary Artery Bypass Grafting: Clinical Case with Brief Literature Review

    by Anastassiya Ganina, Abay Baigenzhin, Elmira Chuvakova, Naizabek Yerzhigit, Anuar Zhunussov, Aizhan Akhayeva, Larissa Kozina, Oleg Lookin, Manarbek Askarov

    Background: Chronically non-healing thoracic wounds after cardiac and non-cardiac thoracotomy, including cases when coronary artery bypass grafting (CABG) is performed, represent a great clinical challenge. It is often that a conservative treatment of the wounds does not provide effective regeneration of the damaged tissues. It is especially critical in patients with infected wounds, in patients owning a systemic infection, and in elderly people. Methods: The article presents a case report of successful treatment of a 63-year-old man with refractory chronic osteomyelitis of the sternum and mediastinitis four years after CABG, complicated by COVID-19 at the time of reconstructive surgery. Due to the low effectiveness of conservative treatment methods, a two-stage approach was applied: radical surgical wound debridement followed by infiltration of the wound with allogenic mesenchymal stromal cells (MSCs) of Wharton’s jelly (WJ-MSCs). Results: This double-stage therapy successfully modulated the inflammatory environment and stimulated granulation, facilitating final thoracoplasty and osteosynthesis. The patient achieved complete healing of the sternum, demonstrating benefits of WJ-MSCs in treating conservative treatment-resistant infections in the surgical wound. Conclusions: The advantages of using perinatal mesenchymal stem cells, with WJ-MSCs as a type of this class of MSCs, were demonstrated in treating chronically infected sternal surgical wounds. We also compared their regenerative properties to other stem cell types like bone marrow MSCs.